What is the current Price Target for the Cidara Therapeutics, Inc. stock?

The average Cidara Therapeutics, Inc. target price is $36.60. This is 105.39% higher than the current stock price. The highest price target is 158.14%, the lowest is 85.19%. 5 Analysts have issued a price target Cidara Therapeutics, Inc. 2026 .

How high will the Cidara Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Cidara Therapeutics, Inc. stock will rise. The performance of stocks, including the Cidara Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Cidara Therapeutics, Inc. stock today?

The performance of Cidara Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Cidara Therapeutics, Inc. stock fall?

The decline in Cidara Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Cidara Therapeutics, Inc. Forecast, price target & analysts

$16.63

6.68% today

Nasdaq, Apr 04, 07:41 pm CET

ISIN

US1717571079

Symbol

CDTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cidara Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Cidara Therapeutics, Inc. Classifications & Recommendation:

Buy

100%

Cidara Therapeutics, Inc. Price Target

Target Price	$36.60
Price	$17.82
Potential	105.39% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Cidara Therapeutics, Inc. 2026 . The average Cidara Therapeutics, Inc. target price is $36.60. This is 105.39% register free of charge higher than the current stock price. The highest price target is $46.00 158.14% register free of charge , the lowest is $33.00 85.19% register free of charge .
	A rating was issued by 6 analysts: 6 Analysts recommend Cidara Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Cidara Therapeutics, Inc. stock has an average upside potential 2026 of 105.39% register free of charge . Most analysts recommend the Cidara Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-26.46	-10.19
	404.00%	61.49%
P/E		negative

6 Analysts have issued a Cidara Therapeutics, Inc. forecast for earnings per share. The average Cidara Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-26.46	404.00%
2025	$-10.19 61.49% Unlock
2026	$-10.24 0.49% Unlock
2027	$-9.65 5.76% Unlock
2028	$-5.59 42.07% Unlock
2029	$-0.82 85.33% Unlock

Current	-0.60	75.10%
2025	-1.75 191.67% Unlock
2026	-1.74 0.57% Unlock
2027	-1.85 6.32% Unlock
2028	-3.19 72.43% Unlock
2029	-21.80 583.39% Unlock

Cidara Therapeutics, Inc....

Current Cidara Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citizens Capital Markets	Locked ➜ Locked	Locked	Mar 12 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 10 2025
Needham	Locked ➜ Locked	Locked	Mar 07 2025
RBC Capital	Locked ➜ Locked	Locked	Dec 13 2024
WBB Securities	Locked ➜ Locked	Locked	Dec 05 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 11 2024
Guggenheim	Locked ➜ Locked	Locked	Nov 08 2024

Analyst Rating	Date
Locked Citizens Capital Markets: Locked ➜ Locked	Mar 12 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 10 2025
Locked Needham: Locked ➜ Locked	Mar 07 2025
Locked RBC Capital: Locked ➜ Locked	Dec 13 2024
Locked WBB Securities: Locked ➜ Locked	Dec 05 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 11 2024
Locked Guggenheim: Locked ➜ Locked	Nov 08 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now